<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03598218</url>
  </required_header>
  <id_info>
    <org_study_id>GLMU-03</org_study_id>
    <nct_id>NCT03598218</nct_id>
  </id_info>
  <brief_title>Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter, Prospective, Randomized, Phase II Trial Evaluating Hypofractionated Versus Conventionally Fractionated Radiotherapy for Initial Distant Metastases Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wei Jiang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangxi Naxishan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanning Monority Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linshan pepole Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Guilin Medical University, China</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Radiotherapy is an important treatment for initial distant metastases nasopharyngeal
      carcinoma. Total dose and fraction size are important prognostic factors for survival,
      although to our knowledge the optimal model has not been well determined to date. The purpose
      of this clinical trial is to investigate the optimal radiation dose to investigate the
      feasibility of decreasing the total dose and increasing the fraction size with the objective
      of achieving a better balance between local control and severe late complications. for
      initial distant metastases nasopharyngeal carcinoma with definitive radiotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine if hypofractionated with a smaller total dose radiation is not inferior to
      standard-dose radiation in progression-free survival for initial distant metastases
      nasopharyngeal carcinoma .

      SECONDARY OBJECTIVES:

      I. To evaluate if hypofractionated with a low total dose radiation is not inferior to
      standard-dose radiation in overall survival and locoregional failure-free survival for
      initial distant metastases nasopharyngeal carcinoma II. To evaluate if hypofractionated with
      a low total dose radiation with chemotherapy decrease treatment-related toxicities

      OUTLINE:

      Patients are randomized to one of the two treatment arms

      ARM 1: Patients receive hypofractionated with a low total dose radiation with induced
      chemotherapy and adjuvant chemotherapy.Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy,
      PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.

      Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week
      chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel
      135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.

      ARM 2: Patients receive standard-dose radiation with concurrent chemotherapy. Standard-dose
      IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 59.4Gy and PTV2 54Gy in 33 fractions, 5 days/week.

      Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week
      chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel
      135mg/m2 D1+Cisplatin 75mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.

      After completion of study therapy, patients are followed up every 3-4 months for 2 years,
      then every 6 months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 13, 2018</start_date>
  <completion_date type="Anticipated">July 13, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 13, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of therapy to locoregional relapse, distant relapse or tumor-related death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of therapy to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional relapse-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of treatment to the time of first locoregional relapse</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant metastasis-free survival</measure>
    <time_frame>2 years</time_frame>
    <description>The time from the first day of treatment to the time of first distant metastasis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Hypofractionated dose IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive hypofractionated with a low total dose radiation with induced chemotherapy and adjuvant chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard-dose IMRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive standard-dose radiation therapy with induced chemotherapy and adjuvant chemotherapy..</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofraction radiation</intervention_name>
    <description>Hypofractionated dose IMRT: GTVnx 60Gy, GTVnd 60Gy, PTV1 50Gy and PTV2 45Gy in 25 fractions, 5 days/week.
Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.</description>
    <arm_group_label>Hypofractionated dose IMRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard dose IMRT</intervention_name>
    <description>Standard dose IMRT: GTVnx 69.69Gy, GTVnd 60-68Gy, PTV1 54.9Gy and PTV2 54Gy in 33 fractions, 5 days/week.
Induced chemotherapy: Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles. After radiation, patients receive adjuvant chemotherapy Paclitaxel 135mg/m2 D1+Cisplatin 80mg/m2 D1(or D1-3), 3-week chemotherapy for 3 cycles.</description>
    <arm_group_label>Standard-dose IMRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with newly histologically confirmed non-keratinizing (according to WHO
             histologically type) Tumor staged as any T or any N with M (according to the 8th AJCC
             edition).

          2. No pregnant female

          3. Age between 18-70

          4. Normal complete blood count level (hemoglobin &gt;10 g/dL, white blood cells ≥4000/μL,
             platelets ≥100 000/μL)

          5. Normal hepatic functions (serum total bilirubin ≤1.6 mg/dL, serum transminase &lt; 2.5
             times higher than upper limit)

          6. Normal renal function (serum creatinine ≤1.5 mg/dL, creatinine clearance ≥60 mL/min)

          7. Karnofsky performance status (KPS) score of at least 70

          8. Without radiotherapy or chemotherapy

          9. Patients must give signed informed consent

        Exclusion Criteria:

          1. Other or mixed pathological type

          2. age &gt; 70 years or &lt;18 years

          3. Prior chemotherapy, radiation, surgical resection or target therapy of the primary
             tumor;

          4. Significant medical or psychiatric illnesses that in the physician's judgment
             (uncontrolled coronary heart disease, cardiomyopathy and/or heart failure requiring
             hospitalization. Uncontrolled hypertension or history of myocardial infarction within
             one year. Uncontrolled diabetes mellitus. Acute bacterial or fungal infection
             requiring intravenous antibiotics;

          5. Refused to sign informed consent form

          6. Concurrent pregnancy or lactation

          7. History of a second malignancy other than nasopharyngeal carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Jiang, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Guilin Medical University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Cai, M.D.</last_name>
    <phone>+86-773-2882906</phone>
    <email>33503706@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangxi Naxishan Hospital</name>
      <address>
        <city>Guilin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu-fei Pan, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Linshan people's hospital</name>
      <address>
        <city>Linshan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi-xin Su</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuzhou Red Cross Hospital</name>
      <address>
        <city>Wuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bin Zhang, M.D.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>July 14, 2018</study_first_submitted>
  <study_first_submitted_qc>July 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2018</study_first_posted>
  <last_update_submitted>July 14, 2018</last_update_submitted>
  <last_update_submitted_qc>July 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guilin Medical University, China</investigator_affiliation>
    <investigator_full_name>Wei Jiang</investigator_full_name>
    <investigator_title>Wei Jiang, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Hypofractionated Radiation</keyword>
  <keyword>initial distant metastases</keyword>
  <keyword>nasopharyngeal carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

